Everlywell went into Shark Tank in November 2017 asking for $1 million for 5% of the company, a pitch that valued the at-home testing startup at $20 million. Lori Greiner agreed to the equity, but changed the structure: instead of handing over $1 million as a conventional investment, she offered a $1 million line of credit at 8% interest in exchange for the same 5% stake.
Julia Cheek accepted.
That distinction matters when looking at what happened next. Everlywell did not simply take a Shark's cash and slowly grow into a bigger version of the same company. It expanded into retail, raised substantial venture capital, moved into COVID-19 testing, acquired healthcare infrastructure businesses, and eventually became part of a much larger parent company called Everly Health.
By 2021, private-market reports were putting the business at a valuation measured in billions rather than millions.
And Everlywell is still operating today.
Everlywell was already doing $2.5 million in sales when Julia Cheek entered the Tank
Cheek founded Everlywell in 2015 after her own frustrating experiences with medical testing. The company's basic proposition was straightforward: let consumers order certain laboratory tests online, collect samples at home, send them to a lab, and receive their results digitally.
The business was not trying to invent a new laboratory test. Its advantage was the consumer experience around existing testing infrastructure.
That distinction was part of what made the company interesting, but it also made the Sharks cautious. At the time of the pitch, Everlywell had generated about $2.5 million in sales, according to Cheek, and was projecting $5.5 million for the following year. Its tests ranged from roughly $69 to $399. (dallasnews.com)
The problem the Sharks saw was scale.
Healthcare testing is not an ordinary e-commerce category. Regulations vary by state, laboratory relationships matter, medical professionals have to be involved, and customer acquisition can be expensive. Several Sharks concluded that Everlywell would require too much capital to compete effectively.
Greiner saw something different. She offered the $1 million line of credit at 8% interest plus 5% equity, and Cheek took the deal. (medcitynews.com)
The Shark Tank deal was a line of credit, not simply $1 million in cash
This is one of the details frequently flattened in later descriptions of Everlywell's Shark Tank appearance.
The headline deal was $1 million for 5%, but the $1 million was structured as a line of credit carrying 8% interest. Greiner received the 5% equity as part of the arrangement. (forbes.com)
So the on-air valuation was still $20 million based on the equity portion Cheek offered, but the financing mechanics were different from a standard $1 million-for-5% equity investment.
That turned out to be a relatively small detail compared with what happened to the company afterward.
Everlywell's retail expansion made the Shark Tank exposure useful
By 2019, Everlywell had moved beyond selling primarily through its own website and Amazon.
Its tests were being distributed through retailers including Target and CVS, while the company was also developing partnerships with healthcare organizations. Forbes reported in April 2019 that Everlywell had raised $50 million and was using the capital to expand its platform and partnerships, including with Humana and Target. (forbes.com)
The company also appeared on Shark Tank again in a later season as an example of Greiner's successful investment portfolio. ABC said in 2020 that Everlywell had passed $65 million in sales. (youtube.com)
That number is useful because it shows the scale change without relying on speculative current "net worth" figures. Everlywell had gone from $2.5 million in sales around its original pitch to more than $65 million in sales within a few years.
The company was no longer just a promising startup with an unusual healthcare business model.
COVID-19 turned Everlywell's home-testing model into a much bigger opportunity
The pandemic created an unusually strong fit between Everlywell's existing infrastructure and what consumers suddenly needed.
In May 2020, the FDA granted emergency use authorization to the Everlywell COVID-19 Test Home Collection Kit. The authorization allowed individuals who had been screened through an online questionnaire reviewed by a healthcare provider to collect a nasal sample at home, with authorized laboratories processing the sample. (fda.gov)
The FDA's records show the Everlywell COVID-19 Home Collection Kit receiving its EUA in May 2020, followed by a direct-to-consumer authorization in February 2021. (fda.gov)
The pandemic accelerated demand dramatically. In late 2020, Everlywell said it expected sales to surpass $100 million for the year, compared with $40 million in 2019, while also reporting that it had distributed more than 500,000 COVID-19 home test kits. (bizjournals.com)
COVID did not create the company's underlying business. It amplified a model Everlywell had already spent years building.
The company raised $175 million at a $1.3 billion valuation in 2020
The next major milestone was financing.
In December 2020, Everlywell announced a $175 million Series D round. The financing valued the company at approximately $1.3 billion. A further $75 million financing from HealthQuest Capital followed in January 2021, with TechCrunch reporting that the $1.3 billion valuation from December still applied. (techcrunch.com)
That is the clearest before-and-after comparison in the company's story.
In 2017, Cheek was pitching a $20 million valuation.
Three years later, Everlywell was being valued at roughly $1.3 billion.
The increase was not simply the result of the Shark Tank appearance. Venture financing, retail distribution, healthcare partnerships, COVID-19 demand and the broader digital-health investment boom all played roles.
In 2021, Everlywell stopped being just Everlywell
The most consequential strategic move came in March 2021.
Everlywell acquired PWNHealth and Home Access Health Corporation, combining them under a new parent company called Everly Health. PWNHealth brought a national clinician network and infrastructure for physician-mediated healthcare, while Home Access Health added experience in self-collected laboratory testing. (prnewswire.com)
The combination was much broader than selling health-test kits.
Everly Health described the businesses as collectively supporting more than 20 million people annually across the United States, Canada and Puerto Rico at the time of the transaction. (prnewswire.com)
Then came another acquisition.
In October 2021, Everly Health bought women's-health company Natalist in an all-cash transaction. The price was not disclosed, making claims about the acquisition's value speculative. (prnewswire.com)
The strategy was becoming clear: Everlywell's original consumer testing business was being turned into one part of a broader diagnostics and healthcare platform.
Everlywell's valuation eventually reached several billion dollars, but the exact number depends on the source
This is where the company's "net worth" gets messy.
Bloomberg reported in March 2021 that the combination with PWNHealth and Home Access Health valued Everlywell at about $2.9 billion, citing people familiar with the transaction. (bloomberg.com)
Later private-market reporting put the company at an even higher valuation. Forbes reported that an estimated Series F financing in December 2021 valued Everly Health at roughly $3.45 billion, while other private-market data sources put the financing valuation around $3.5 billion. (forbes.com)
Those figures should not be treated as a current audited company valuation. Everly Health is privately held, so there is no public stock price establishing what the entire company is worth today.
The useful conclusion is narrower: the $20 million valuation Cheek proposed on Shark Tank was followed by private financing and transactions that valued the broader business in the low-single-digit billions.
That is a very different claim from saying Everlywell is definitively "worth $3.5 billion today."
Everlywell is still operating, but the product has expanded far beyond the original pitch
Everlywell did not disappear into Everly Health.
The Everlywell consumer brand remains active in 2026. Its current offerings include at-home testing as well as newer services that connect consumers with laboratory testing through clinician review.
One current offering, Everlywell Everywhere, lets customers choose from more than 900 laboratory tests, have a board-certified clinician review the request, and then visit one of more than 7,000 listed laboratory locations. Everlywell says the program is currently in early access. (everlywell.com)
The company has also continued developing its at-home testing products. In 2025, Everlywell launched Everlywell 360, a membership-oriented health testing product built around 83 biomarkers and a clinician-reviewed care plan. (everlywell.com)
Its current site still identifies Everly Health, Inc. as the owner and operator of Everlywell. (everlywell.com)
So "what happened to Everlywell?" has a slightly misleading premise.
It did not get acquired by another company and vanish. Everlywell became the consumer-facing brand inside a much larger healthcare business.
Lori Greiner's Everlywell investment became one of Shark Tank's notable healthcare wins
Greiner's investment is now regularly cited among the show's major successes, but the real story is less about a $1 million Shark Tank check than about what happened after the cameras left.
Everlywell already had traction when Cheek walked into the Tank. The company had customers, millions in sales and a business model that was difficult to scale. Greiner supplied capital and retail-marketing expertise at a point when the company was trying to prove that model could work at national scale.
Then Everlywell benefited from forces much larger than Shark Tank: the expansion of direct-to-consumer healthcare, COVID-19 testing demand, a surge in digital-health investment and consolidation across healthcare services.
A company pitched at $20 million in 2017 was being valued at roughly $1.3 billion by late 2020, and around $2.9 billion to $3.5 billion in 2021 depending on the transaction and source. (techcrunch.com)
Today, the more revealing measure is not an estimated billionaire valuation. It is the company's shape.
Everlywell began by making a lab test easier to order from home. A decade later, the brand sits inside Everly Health alongside clinician networks, laboratory infrastructure, women's health products and broader diagnostic services.
That is what the Shark Tank bet ultimately became: not just a successful test-kit company, but the consumer entry point for a much larger healthcare platform.
